1. PI3K/Akt/mTOR Anti-infection
  2. Akt Bacterial
  3. Oridonin

Oridonin  (Synonyms: 冬凌草甲素; NSC-250682; Isodonol)

目录号: HY-N0004 纯度: 99.89%
COA 产品使用指南

Oridonin (NSC-250682) 是从 Rabdosia rubescens 中得到的二萜,为 AKT 抑制剂,对 AKT1AKT2IC50 值分别为 8.4 和 8.9 μM;Oridonin 具有抗肿瘤、抗菌、抗炎等功效。

MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

Oridonin Chemical Structure

Oridonin Chemical Structure

CAS No. : 28957-04-2

1.  客户无需承担相应的运输费用。

2.  同一机构(单位)同一产品试用装仅限申领一次,同一机构(单位)一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ¥550
In-stock
1 mg ¥156
In-stock
5 mg ¥312
In-stock
10 mg ¥500
In-stock
50 mg ¥1000
In-stock
100 mg ¥1600
In-stock
200 mg ¥2600
In-stock
500 mg ¥5200
In-stock
1 g   询价  
5 g   询价  

* Please select Quantity before adding items.

Customer Review

Other Forms of Oridonin:

查看 Akt 亚型特异性产品:

  • 生物活性

  • 实验参考方法

  • 纯度 & 产品资料

  • 参考文献

生物活性

Oridonin (NSC-250682), a diterpenoid isolated from Rabdosia rubescens, acts as an inhibitor of AKT, with IC50s of 8.4 and 8.9 μM for AKT1 and AKT2; Oridonin possesses anti-tumor, anti-bacterial and anti-inflammatory effects.

IC50 & Target[1]

Akt1

8.4 μM (IC50)

Akt2

8.9 μM (IC50)

细胞效力
(Cellular Effect)
Cell Line Type Value Description References
A549 IC50
> 10 μM
Compound: 20
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
[PMID: 23819871]
A549 IC50
13.45 μM
Compound: Oridonin
Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
[PMID: 31494472]
A549 IC50
17.8 μM
Compound: 1
Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
[PMID: 31202992]
A549 IC50
18.15 μM
Compound: 1
Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
[PMID: 30921757]
A549 IC50
30.4 μM
Compound: 1; ORI
Antiproliferative activity against human A549 cells incubated for 72 hrs by CCK8 cells
Antiproliferative activity against human A549 cells incubated for 72 hrs by CCK8 cells
[PMID: 31200238]
Bel-7402 IC50
5.41 μM
Compound: 1
Antiproliferative activity against human Bel7402 cells after 72 hrs by MTT assay
Antiproliferative activity against human Bel7402 cells after 72 hrs by MTT assay
[PMID: 28165738]
Bel-7402 IC50
7.85 μM
Compound: 1
Antiproliferative activity against human Bel7402 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Antiproliferative activity against human Bel7402 cells assessed as reduction in cell viability after 72 hrs by MTT assay
[PMID: 30921757]
Bel-7402 IC50
8.31 μM
Compound: 1
Antiproliferative activity against human Bel7402 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Antiproliferative activity against human Bel7402 cells assessed as reduction in cell viability after 72 hrs by MTT assay
[PMID: 31202992]
Bel-7402 IC50
9.59 μM
Compound: Oridonin
Antiproliferative activity against human Bel7402 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Antiproliferative activity against human Bel7402 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
[PMID: 30981113]
BEL-7404 tumor cell line IC50
17.92 μM
Compound: 1
Antiproliferative activity against human Bel7404 cells after 48 hrs by MTT assay
Antiproliferative activity against human Bel7404 cells after 48 hrs by MTT assay
[PMID: 28165738]
DU-4475 IC50
16.95 μM
Compound: 1
Antiproliferative activity against human DU4475 cells after 72 hrs by MTT assay
Antiproliferative activity against human DU4475 cells after 72 hrs by MTT assay
[PMID: 32610904]
H22 IC50
4.88 μM
Compound: 1
Antiproliferative activity against mouse H22 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against mouse H22 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
[PMID: 35121201]
HCC1806 IC50
21.74 μM
Compound: 1
Antiproliferative activity against human HCC1806 cells after 72 hrs by MTT assay
Antiproliferative activity against human HCC1806 cells after 72 hrs by MTT assay
[PMID: 32610904]
HCC1937 IC50
8.27 μM
Compound: 1
Antiproliferative activity against human HCC1937 cells after 72 hrs by MTT assay
Antiproliferative activity against human HCC1937 cells after 72 hrs by MTT assay
[PMID: 32610904]
HCT-116 IC50
6.84 μM
Compound: Oridonin
Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
[PMID: 30981113]
HeLa IC50
17.28 μM
Compound: 1
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
[PMID: 35121201]
HepG2 IC50
8.12 μM
Compound: 1; ORI
Antiproliferative activity against human HepG2 cells incubated for 72 hrs by CCK8 cells
Antiproliferative activity against human HepG2 cells incubated for 72 hrs by CCK8 cells
[PMID: 31200238]
HL-60 IC50
2.5 μM
Compound: 20
Cytotoxicity against human HL60 cells after 48 hrs by MTT assay
Cytotoxicity against human HL60 cells after 48 hrs by MTT assay
[PMID: 23819871]
HL-60 IC50
9.46 μM
Compound: 1
Antiproliferative activity against human HL60 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Antiproliferative activity against human HL60 cells assessed as reduction in cell viability after 72 hrs by MTT assay
[PMID: 30921757]
K562 IC50
4.32 μM
Compound: 1
Antiproliferative activity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
[PMID: 35121201]
K562 IC50
4.33 μM
Compound: 1
Antiproliferative activity against human K562 cells after 72 hrs by MTT assay
Antiproliferative activity against human K562 cells after 72 hrs by MTT assay
[PMID: 28165738]
K562 IC50
4.64 μM
Compound: 1
Antiproliferative activity against human K562 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Antiproliferative activity against human K562 cells assessed as reduction in cell viability after 72 hrs by MTT assay
[PMID: 30921757]
K562 IC50
4.79 μM
Compound: 1
Antiproliferative activity against human K562 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Antiproliferative activity against human K562 cells assessed as reduction in cell viability after 72 hrs by MTT assay
[PMID: 31202992]
KB 3-1 IC50
13.24 μM
Compound: 1
Antiproliferative activity against human KB-3-1 cells after 48 hrs by MTT assay
Antiproliferative activity against human KB-3-1 cells after 48 hrs by MTT assay
[PMID: 28165738]
L02 IC50
17.47 μM
Compound: 1; ORI
Cytotoxicity against human LO2 cells incubated for 72 hrs by CCK8 cells
Cytotoxicity against human LO2 cells incubated for 72 hrs by CCK8 cells
[PMID: 31200238]
L02 IC50
18.68 μM
Compound: 1
Cytotoxicity against human L02 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human L02 cells assessed as reduction in cell viability after 72 hrs by MTT assay
[PMID: 31202992]
L02 IC50
19.53 μM
Compound: 1
Cytotoxicity against human L02 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human L02 cells assessed as reduction in cell viability after 72 hrs by MTT assay
[PMID: 30921757]
L02 IC50
34.32 μM
Compound: 1
Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
[PMID: 35121201]
L02 IC50
42.25 μM
Compound: Oridonin
Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
[PMID: 35428012]
L02 IC50
6.97 μM
Compound: Oridonin
Cytotoxicity in human L02 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity in human L02 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
[PMID: 30981113]
MCF7 IC50
> 10 μM
Compound: 20
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
[PMID: 23819871]
MCF7 IC50
11.11 μM
Compound: 1
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
[PMID: 35121201]
MCF7 IC50
17.56 μM
Compound: Oridonin
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
[PMID: 30981113]
MCF7 IC50
17.89 μM
Compound: 1
Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
[PMID: 28165738]
MCF7 IC50
21.97 μM
Compound: Oridonin
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
[PMID: 31494472]
MCF7 IC50
6.6 μM
Compound: 126
Antiproliferative activity against ER-positive human MCF7 cells after 48 hrs by MTT assay
Antiproliferative activity against ER-positive human MCF7 cells after 48 hrs by MTT assay
[PMID: 35033884]
MDA-MB-231 IC50
11.62 μM
Compound: 1
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
[PMID: 35121201]
MDA-MB-231 IC50
17.92 μM
Compound: 1
Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay
[PMID: 32610904]
MDA-MB-231 EC50
29.4 μM
Compound: Oridonin
Antiproliferative activity against human MDA-MB-231 cells incubated for 48 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells incubated for 48 hrs by MTT assay
[PMID: 30981113]
MDA-MB-453 IC50
6.67 μM
Compound: 1
Antiproliferative activity against human MDA-MB-453 cells after 72 hrs by MTT assay
Antiproliferative activity against human MDA-MB-453 cells after 72 hrs by MTT assay
[PMID: 32610904]
MDA-MB-468 IC50
17.28 μM
Compound: 1
Antiproliferative activity against human MDA-MB-468 cells after 72 hrs by MTT assay
Antiproliferative activity against human MDA-MB-468 cells after 72 hrs by MTT assay
[PMID: 32610904]
MGC-803 IC50
14.13 μM
Compound: Oridonin
Antiproliferative activity against human MGC803 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
Antiproliferative activity against human MGC803 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
[PMID: 31494472]
MGC-803 IC50
15.11 μM
Compound: 1
Antiproliferative activity against human MGC-803 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human MGC-803 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
[PMID: 35121201]
MGC-803 IC50
9.06 μM
Compound: 1
Antiproliferative activity against human MGC803 cells after 72 hrs by MTT assay
Antiproliferative activity against human MGC803 cells after 72 hrs by MTT assay
[PMID: 28165738]
NCI/ADR-RES IC50
26.18 μM
Compound: 1
Antiproliferative activity against human MCF7/ADR cells after 72 hrs by MTT assay
Antiproliferative activity against human MCF7/ADR cells after 72 hrs by MTT assay
[PMID: 32610904]
NCI-H460 IC50
20.51 μM
Compound: 1
Antiproliferative activity against human NCI-H460 cells after 48 hrs by MTT assay
Antiproliferative activity against human NCI-H460 cells after 48 hrs by MTT assay
[PMID: 28165738]
PBMC IC50
> 50 μM
Compound: 1
Cytotoxicity against human PBMC assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human PBMC assessed as reduction in cell viability after 72 hrs by MTT assay
[PMID: 31202992]
PC-3 IC50
10.07 μM
Compound: 1
Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 72 hrs by MTT assay
[PMID: 30921757]
PLC-PRF-5 IC50
7.41 μM
Compound: 1; ORI
Antiproliferative activity against human PLC/PRF/5 cells incubated for 72 hrs by CCK8 cells
Antiproliferative activity against human PLC/PRF/5 cells incubated for 72 hrs by CCK8 cells
[PMID: 31200238]
RAW264.7 IC50
5.2 μM
Compound: 20
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 18 hrs by Griess method
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 18 hrs by Griess method
[PMID: 23819871]
RPMI-8226 IC50
9.25 μM
Compound: 1; ORI
Antiproliferative activity against human RPMI8226 cells incubated for 72 hrs by CCK8 cells
Antiproliferative activity against human RPMI8226 cells incubated for 72 hrs by CCK8 cells
[PMID: 31200238]
SGC-7901 IC50
7.13 μM
Compound: 1
Antiproliferative activity against human SGC7901 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Antiproliferative activity against human SGC7901 cells assessed as reduction in cell viability after 72 hrs by MTT assay
[PMID: 30921757]
SGC-7901 IC50
7.87 μM
Compound: 1
Antiproliferative activity against human SGC7901 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Antiproliferative activity against human SGC7901 cells assessed as reduction in cell viability after 72 hrs by MTT assay
[PMID: 31202992]
SK-BR-3 IC50
8.49 μM
Compound: 1
Antiproliferative activity against human SK-BR-3 cells after 72 hrs by MTT assay
Antiproliferative activity against human SK-BR-3 cells after 72 hrs by MTT assay
[PMID: 32610904]
SMMC-7721 IC50
> 10 μM
Compound: 20
Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT assay
Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT assay
[PMID: 23819871]
SMMC-7721 IC50
12.57 μM
Compound: 1
Antiproliferative activity against human SMMC-7221 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human SMMC-7221 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
[PMID: 35121201]
SW480 IC50
> 10 μM
Compound: 20
Cytotoxicity against human SW480 cells after 48 hrs by MTT assay
Cytotoxicity against human SW480 cells after 48 hrs by MTT assay
[PMID: 23819871]
SW480 IC50
11.63 μM
Compound: 1
Antiproliferative activity against human SW480 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human SW480 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
[PMID: 35121201]
T47D IC50
7.56 μM
Compound: 1
Antiproliferative activity against human T47D cells after 72 hrs by MTT assay
Antiproliferative activity against human T47D cells after 72 hrs by MTT assay
[PMID: 32610904]
TE-1 IC50
12.73 μM
Compound: Oridonin
Antiproliferative activity against human TE1 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
Antiproliferative activity against human TE1 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
[PMID: 31494472]
U-87MG ATCC IC50
14.05 μM
Compound: 1
Antiproliferative activity against human U-87 MG cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human U-87 MG cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
[PMID: 35121201]
体外研究
(In Vitro)

Oridonin 是一种 ATP 竞争性 AKT 抑制剂,对 AKT1AKT2 的 IC50 分别为 8.4 和 8.9 μM。Oridonin (5、10 或 20 μM) 明显抑制 KYSE70、KYSE410 和 KYSE450 ESCC 细胞的生长,这是通过靶向 AKT1/2 实现的。Oridonin (10 或 20 μM) 可导致 KYSE70、KYSE410 和 KYSE450 细胞的 G2/M 期细胞周期停滞,并在 20 μM 浓度下诱导这三种细胞系的细胞凋亡。此外,Oridonin (5、10 或 20 μM) 与顺铂或 5-FU 联合使用可增强对食管鳞状细胞癌 (ESCC) 细胞生长的抑制[1]。Oridonin (0.1 和 1 μM) 优先抑制 AKT/mTOR 信号传导。Oridonin (1 μM) 还选择性抑制 AKT 信号传导过度活跃的乳腺癌细胞的生长[2]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

在携带 EG9 和 HEG18 肿瘤细胞的严重联合免疫缺陷症 (SCID) 小鼠中,Oridonin (160 mg/kg,口服) 可显著抑制肿瘤生长,且体重没有明显减轻。Oridonin 治疗还可抑制小鼠 Ki-67、磷酸化 AKT、GSK-3β 或 mTOR 的表达[1]。Oridonin (15 mg/kg,腹腔注射) 可抑制裸鼠乳腺癌细胞生长,导致 AKT 信号过度激活[2]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial
分子量

364.43

Formula

C20H28O6

CAS 号
性状

固体

颜色

White to off-white

中文名称

冬凌草甲素

结构分类
初始来源
运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 1 year
-20°C 6 months
溶解性数据
细胞实验: 

DMSO 中的溶解度 : 62.5 mg/mL (171.50 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.7440 mL 13.7201 mL 27.4401 mL
5 mM 0.5488 mL 2.7440 mL 5.4880 mL
查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 1 year; -20°C, 6 months。-80°C储存时,请在1年内使用, -20°C储存时,请在6个月内使用。

  • 摩尔计算器

  • 稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量
=
浓度
×
体积
×
分子量 *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start)

C1

×
体积 (start)

V1

=
浓度 (final)

C2

×
体积 (final)

V2

动物实验:

请根据您的 实验动物和给药方式 选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:
——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 方案 一

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.08 mg/mL (5.71 mM); 澄清溶液

    此方案可获得 ≥ 2.08 mg/mL(饱和度未知)的澄清溶液。

    1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;再向上述体系中加入 50 μL Tween-80,混合均匀;然后再继续加入 450 μL 生理盐水 定容至 1 mL

    生理盐水的配制:将 0.9 g 氯化钠,溶解于 ddH₂O 并定容至 100 mL,可以得到澄清透明的生理盐水溶液。
  • 方案 二

    请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.08 mg/mL (5.71 mM); 澄清溶液

    此方案可获得 ≥ 2.08 mg/mL(饱和度未知)的澄清溶液。

    1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液 中,混合均匀。

    2 g SBE-β-CD(磺丁基醚 β-环糊精)粉末定容于 10 mL 的生理盐水中,完全溶解至澄清透明。

以下溶解方案,请直接配制工作液。建议现用现配,在短期内尽快用完。 以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比; 如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶。

  • 方案 一

    请依序添加每种溶剂: 10% 1-Methyl-2-pyrrolidinone    90% PEG300

    Solubility: ≥ 5 mg/mL (13.72 mM); 澄清溶液

动物溶解方案计算器
请输入动物实验的基本信息:

给药剂量

mg/kg

动物的平均体重

g

每只动物的给药体积

μL

动物数量

由于实验过程有损耗,建议您多配一只动物的量
请输入您的动物体内配方组成:
%
DMSO +
+
%
Tween-80 +
%
Saline
如果您的动物是免疫缺陷鼠或者体弱鼠,建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。
方案所需 助溶剂 包括:DMSO ,均可在 MCE 网站选购。 Tween 80,均可在 MCE 网站选购。
计算结果
工作液所需浓度 : mg/mL
储备液配制方法 : mg 药物溶于 μL  DMSO(母液浓度为 mg/mL)。
您所需的储备液浓度超过该产品的实测溶解度,以下方案仅供参考,如有需要,请与 MCE 中国技术支持联系。
动物实验体内工作液的配制方法 : 取 μL DMSO 储备液,加入 μL  μL ,混合均匀至澄清,再加 μL Tween 80,混合均匀至澄清,再加 μL 生理盐水
连续给药周期超过半月以上,请谨慎选择该方案。
请确保第一步储备液溶解至澄清状态,从左到右依次添加助溶剂。您可采用超声加热 (超声清洗仪,建议频次 20-40 kHz),涡旋吹打等方式辅助溶解。
纯度 & 产品资料

纯度: 99.89%

参考文献
Kinase Assay
[1]

For the AKT kinase assay, the ADP-Glo™ Kinase Assay Kit is used. Active AKT1 or AKT2 kinase and inactive GSK-3β as substrate are mixed by 1× reaction buffer and then added to a white 96-well plate. Pure ATP provided in the kit is serially diluted obtain a final concentration of 0, 1, 10, 50, and 100 μM. GSK-3β is added to reach a final concentration of 2.5, 5, 10 or 20 μM and DMSO is used as a control. The mixed solution is incubated at room temperature and luciferase activity is measured using the Luminoskan Ascent plate reader[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Assay
[1]

Cells are seeded (6×103 cells/well for KYSE70; 2.5×103 cells/well for KYSE410; 2×103 cells/well for KYSE450) in 96-well plates and incubated for 24 h and then treated with different amounts of Oridonin or vehicle. After incubation for 24, 48 or 72 h, cell proliferation is measured by the MTT assay. For anchorage-independent cell growth assessment, cells (2.5, 5 or 10 μM Oridonin) suspended in complete medium are added to 0.3% agar with vehicle, 2.5, 5 or 10 μM Oridonin in a top layer over a base layer of 0.5% agar with vehicle, 2.5, 5 or 10 μM Oridonin. The cultures are maintained at 37°C in a 5% CO2 incubator for 3 weeks and then colonies are visualized under a microscope and counted using the Image-Pro Plus software program[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration
[2]

Mice[2]
Breast cancer cells are harvested and resuspended in 40% Matrigel-Basement Membrane Matrix, LDEV-free, and then injected (100 μL per site) into the fourth pair of mammary fat pads of nude mice (CrTac: NCr-Foxn1nu). Tumors are measured in two dimensions using manual calipers. Tumor volume is calculated using the formula: Volume = 0.5 × length × width × width. Tumor volume is measured every 2-3 days. Upon harvesting, tumors are fixed in formalin overnight and then in 70% ethanol for histopathology analysis. Mice are treated with Oridonin (15 mg/kg) in 1% Pluronic F68 or vehicle (1% Pluronic F68) daily by intraperitoneal (IP) injection. BEZ235 is reconstituted 1:9 in 1-methyl-2 pyrolidone and polyethylene glycol 300 (PEG300) Mice are treated with this compound formulation at 45 mg/kg daily (QD) by oral gavage[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

参考文献

完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 1 year; -20°C, 6 months。-80°C储存时,请在1年内使用, -20°C储存时,请在6个月内使用。

可选溶剂 浓度 溶剂体积 质量 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.7440 mL 13.7201 mL 27.4401 mL 68.6003 mL
5 mM 0.5488 mL 2.7440 mL 5.4880 mL 13.7201 mL
10 mM 0.2744 mL 1.3720 mL 2.7440 mL 6.8600 mL
15 mM 0.1829 mL 0.9147 mL 1.8293 mL 4.5734 mL
20 mM 0.1372 mL 0.6860 mL 1.3720 mL 3.4300 mL
25 mM 0.1098 mL 0.5488 mL 1.0976 mL 2.7440 mL
30 mM 0.0915 mL 0.4573 mL 0.9147 mL 2.2867 mL
40 mM 0.0686 mL 0.3430 mL 0.6860 mL 1.7150 mL
50 mM 0.0549 mL 0.2744 mL 0.5488 mL 1.3720 mL
60 mM 0.0457 mL 0.2287 mL 0.4573 mL 1.1433 mL
80 mM 0.0343 mL 0.1715 mL 0.3430 mL 0.8575 mL
100 mM 0.0274 mL 0.1372 mL 0.2744 mL 0.6860 mL
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称:

 

* 需求量:

* 客户姓名:

 

* Email:

* 电话:

 

* 公司或机构名称:

   留言给我们:

Bulk Inquiry

Inquiry Information

产品名称:
Oridonin
目录号:
HY-N0004
需求量: